The 17-member poly(ADP-ribose) polymerase (PARP) family of proteins, also known as ADP-ribosyltransferase diphtheriatoxin-like proteins (ARTD1-17), has garnered much attention during the past decade as a target for cancer therapy owing to the success of PARP inhibitors in preclinical trials
1
. The primary function of PARPs is to post-translationally modify target proteins with ADP-ribose using NAD + as substrate 2 . The four best-studied family members -PARP1 and PARP5A, as well as their close functional homologues PARP2 and PARP5B, respectively -all generate poly(ADPribose) (PAR). However, most PARPs do not generate PAR, and they instead attach ADPribose as a monomer (MAR) onto target proteins 3 . Recent data have shown that many of these MAR-generating PARPs might have cancer-relevant functions (TABLE 1) . Therefore, understanding the distinction between PAR and MAR synthesis is important, as these protein modifications function by different mechanisms that will probably affect the efficacy of current and novel PARP inhibitors.
This Opinion article describes the key functional differences between MAR and PAR, and it discusses recently discovered PARP functions that might be cancerassociated. Most of these functions involve MAR-generating PARPs, which identifies this class of PARP proteins as potentially important targets for cancer therapy.
MAR versus PAR
Multiple characteristics of the PARP catalytic domain are important in determining whether a PARP generates PAR or MAR modifications. These characteristics include the specific amino acid residues that bind to NAD + and catalyse the transfer reaction, as well as structural elements that define the substrate and acceptor binding pockets (FIG. 1; TABLE 1) . PAR-generating PARPs contain a His-Tyr-Glu (HYE) motif in which the histidine and tyrosine are involved in NAD + binding and coordination, whereas the glutamate is required for PAR transfer and elongation activity 4 . Most PARP family members lack this glutamate and instead contain leucine, isoleucine or valine and are predicted to or have been shown in vitro to generate MAR using automodification reactions containing purified PARP and labelled NAD + (TABLE 1) .
In addition, PARP9 (also known as B aggressive lymphoma 1 (BAL1)) and PARP13 (also known as ZC3HAV1), which lack the histidine, are predicted to be enzymatically inactive and do not show automodification activity 3, 5 (TABLE 1) . Structural characteristics of the substrate and acceptor binding pockets that affect enzymatic activity include the donor loop (D-loop), which interacts with the substrate NAD + and is thought to function as a 'lid' to hold NAD + within the catalytic pocket 6 (FIG. 1) . Additionally, the acceptor pocket is partly lined by the loop between β-sheets 4 and 5, which is referred to as the acceptor loop (FIG. 1) . This loop is implicated in the binding of protein substrate for MAR-and PAR-generating PARPs, or an incoming ADP-ribose unit for PAR-generating PARPs 7, 8 . Both PAR and MAR function as traditional post-translational modifications that can alter the function of target proteins. However, PAR has a unique chemistry and structure compared with MAR and this further influences its biological function (FIG. 2) . PAR is composed of ADP-ribose residues that are connected via glycosidic bonds, which impart characteristics of both nucleic acids and polysaccharides. PAR can contain both linear and branched linkages, although branched linkages are less frequent (approximately one per 20-50 linear linkages) 9 (FIG. 2) . When generated in vitro, PAR can be sizeable, containing up to 200 ADP-ribose residues 10 . In cells, polymers of such a size probably cannot be found constitutively, as PAR that is purified from tissue contains a maximum of 30 residues 11 . However, they can occur transiently, as treatment with DNA-damaging agents results in PAR chain lengths that are comparable to those produced in vitro 12 . Thus, the chemistry, high negative charge density and size of PAR results in a molecule that can function as a high-density protein-binding scaffold 13 (FIG. 2) . There are several examples of this function. DNA repair proteins are recruited to sites of DNA damage by binding directly to PAR that is attached to PARP1 and histones 14 . Similarly, PAR scaffolds have been implicated in the regulation of nuclear factor-κB (NF-κB) signalling 15 , Cajal body function 16 and cytoplasmic stress granule assembly 17 , and they are also present at the mitotic spindle pole 18 . Although both PAR and MAR can bind to proteins, the complexity of the recruitment signal, the number of binding proteins, the number of identified binding domains and the amount of protein that can bind to PAR greatly exceeds that of MAR. There are four known high-affinity PAR binding domains -Trp-Trp-Glu (WWE) 19 , PARbinding zinc finger (PBZ) 20 and 'macro' (REF. 21 ) domains, as well as a loosely defined PAR-binding motif (PBM) 22 (reviewed in REFS 13, 23) (FIG. 2) ; collectively, these domains are found in more than 800 proteins, including PARPs 20, 22, 24, 25 (TABLE 1) . By contrast, the only MAR-binding domain that has been identified so far is the macro domain, which has been shown to bind to both free 21 and protein-attached 26, 27 MAR and PAR, although the binding affinities for the two types of ADP-ribose modifications vary among different macro domains 28 . However, although many functions for MAR are now identified 29 , the biological relevance of protein binding to MAR has not been extensively studied and is therefore unclear.
As a regulatory molecule, MAR is thought to be evolutionarily ancient, because viruses such as T4 bacteriophage and certain pathogenic bacteria encode mono-ADP-ribosyltransferases (mARTs) that modify host proteins with MAR to mediate pathogenicity [30] [31] [32] . In addition Abstract | Poly(ADP-ribose) polymerases (PARPs) modify target proteins posttranslationally with poly(ADP-ribose) (PAR) or mono(ADP-ribose) (MAR) using NAD + as substrate. The best-studied PARPs generate PAR modifications and include PARP1 and the tankyrase PARP5A, both of which are targets for cancer therapy with inhibitors in either clinical trials or preclinical development. There are 15 additional PARPs, most of which modify proteins with MAR, and their biology is less well understood. Recent data identify potentially cancer-relevant functions for these PARPs, which indicates that we need to understand more about these PARPs to effectively target them.
to PARPs, eukaryotes contain multiple MAR-generating enzymes, all of which require NAD + as substrate. These include two members of the sirtuin (SIRT) family, SIRT4 (REF. 33 ) and SIRT6 (REF. 34 ), and the eukaryotic ART family 35 . In mammals, three of the five ARTs are active as arginine-ADP-ribosyltransferases 35 . Although SIRTs can generate MAR intracellularly, the ARTs that are found in humans probably do not, as they are either glycosylphosphatidylinositol-anchored or secreted ecto-enzymes 35 . Intracellular MAR modifications in humans have long been identified, although in many cases the specific enzymes that are responsible for their synthesis are unknown. Known targets of MAR modification include the cytoskeletal proteins actin 36, 37 and desmin 38 , the protein folding chaperone GRP78 (also known as BIP) [39] [40] [41] [42] and heterotrimeric G proteins [43] [44] [45] [46] [47] . Each of these proteins is MARylated on arginines instead of the canonical lysine, glutamate or aspartate residues that are known to be PARylated by PARPs [48] [49] [50] . However, as the amino acid targets of most MARylating PARPs have not been identified, it is possible that among these PARPs are the proteins responsible for arginine modification of the above targets. In fact, several new functions that have been ascribed to MAR-generating PARPs, including actin cytoskeletal regulation, membrane UPR. The UPR is a cellular adaptation to endoplasmic reticulum (ER) stress that is triggered by an increase in misfolded proteins within the ER lumen or by extracellular stressors such as nutrient or oxygen deprivation 65 . Because of the cytoprotective function of the UPR, its upregulation is a hallmark of many cancers, owing in part to the highly oxidative tumour microenvironment and the high rate of protein synthesis that is found in cancer cells 66 . During severe stress or prolonged UPR activation, the UPR activates a distinct transcriptional programme to induce UPR-dependent apoptosis 65 . Activation of this apoptotic programme makes the UPR a particularly attractive target for cancer therapies 54 . In humans, two highly homologous transmembrane kinases -PKR-like ER kinase (PERK; also known as eIF2αK3) and inositol-requiring enzyme 1α (IRE1α) -function as ER stress sensors that regulate separate but interconnected signalling networks in the UPR 65 . A third ER stress sensor, ATF6, is not regulated by PARP activity. UPR activation by these kinases results in a general decrease in translation, while transcription and translation of stress-specific proteins is increased to restore ER homeostasis 65 . Both PERK and IRE1α are targets for cancer therapies [67] [68] [69] . PARP16 is an ER transmembrane protein with a cytoplasmic catalytic domain that shows MAR activity 51, 70 . During UPR activation, PARP16 enzymatic activity is substantially increased, which results in PARP16 automodification and modification of IRE1α and PERK with MAR 51 . Karyopherin β1, which is part of the nuclear trafficking machinery, has also been identified as a target of PARP16 (REF. 70 ), suggesting that PARP16 has additional non-UPR-dependent functions. MARylation of IRE1α and PERK is sufficient to activate these enzymes in vitro, and knockdown of PARP16 in HeLa cells results in defective UPR activation, with PERK and IRE1α signalling markedly reduced 51 . Together, these results suggest that PARP16 is crucial for activating these enzymes in vertebrates and/or maintaining their 'on' state 51 . In addition, PARP16 is phosphorylated by PERK in vitro 51 , suggesting that the activation of PARP16 could be regulated by PERK phosphorylation, similar to PARP1 activation being regulated by ERK phosphorylation 71, 72 and PARP5A activation being regulated by glycogen synthase kinase 3β (GSK3β) phosphorylation 73 . Thus, PERK and PARP16 seem to regulate each other via a positive-feedback loop.
As PARP16 regulates UPR activation, as well as PERK and IRE1α signalling, it is an attractive candidate for the therapeutic inhibition of UPR signalling in cancers 54 with or without known UPR-activating agents such as heat shock protein 90 (HSP90) 74 and 26S proteasome inhibitors 75 . Data suggest that this approach is feasible, as small interfering RNA (siRNA)-mediated knockdown of PARP16 renders HeLa cells highly sensitive to UPR activation, resulting in increased cell death compared with PARP16 siRNA in HeLa cells in which the UPR has not been triggered 51 . Therefore, the requirement of PARP16 function for UPR activation makes it an attractive candidate to target cancers that have an increased reliance on the UPR for survival (TABLE 1) .
Cytoplasmic stress response. Cytoplasmic stressors, including viral infection, oxidative stress, heat shock, hypoxia and ER stress result in eukaryotic translation initiation factor 2α (eIF2α) phosphorylation, inhibition of cap-dependent mRNA translation and the assembly of stress granules -large ribonucleoprotein complexes that contain mRNA, RNA-binding proteins and 40S ribosomal subunits 76 . PAR, five different PARPs and PAR glycohydrolase (PARG) -an enzyme that is specific for the hydrolysis of PAR -are enriched in stress granules on stress induction, and PAR synthesis and turnover dynamics regulate the kinetics of stress granule formation and disassembly 17 .
Of the stress granule-associated PARPs, only PARP5A has PAR synthesis activity, whereas PARP12, PARP14 (also known as BAL2 on the basis of its homology to PARP9) and PARP15 generate MAR, and PARP13 is inactive, but present 3, 17 . Under hypoxic or oxidative stress, stress granules inhibit the induction of apoptosis through the JUN N-terminal kinase (JNK)-MAPK signalling pathway via the sequestration of receptor of activated protein kinase C1 (RACK1; also known as GNB2L1) -a mediator of the MAPK pathway 77 . Similarly, sequestration of regulatory associated protein of mTOR (RAPTOR) in stress granules in the presence of oxidative stress prevents apoptosis that is induced by hyperactivation of mTOR complex 1 (mTORC1) 78 . Astrin (also known as SPAG5), a protein that is upregulated in cancer cells, mediates the localization of RAPTOR to stress granules, and oxidative stress-induced apoptosis is increased in cancer cells in which stress granule assembly is inhibited or expression of astrin is knocked down using siRNAs 78 . Cancer cells in solid tumours are subject to multiple stress granule-inducing stresses, such as hypoxia and oxidative stress, both of which are associated with chemoresistance 79 . For example, solid tumours are mostly resistant to apoptosis induction that is mediated by bortezomib, a 26S proteasome . Interestingly, treatment with bortezomib was shown to induce stress granule assembly in multiple cancer cell lines, and inhibition of stress granule formation promoted bortezomib-mediated apoptosis, further supporting the protective effects of stress granules in cancer cell survival 81 . Therefore, targeting the PARPs that function in stress granule assembly could be a strategy to sensitize solid tumours to chemotherapy (TABLE 1) . miRNA-argonaute 2 silencing pathway. mi RNAs are small, non-coding RNAs that regulate gene expression via posttranscriptional mechanisms. miRNA function is mediated by the RNA-induced silencing complex (RISC), the core components of which are argonaute (AGO) proteins that bind to the miRNA-mRNA duplex and mediate post-transcriptional silencing 82 . AGO proteins are modified by PAR during normal conditions, but the level of PAR modification increases during cellular stress (including that induced by viral infection and oxidative stress), resulting in decreased miRNA-dependent silencing activity 17, 56 . PARP13 seems to be important for the regulation of AGO2 function, as PARP13 knockdown upregulates AGO2 silencing activity under stress and non-stress conditions 17, 56 . Although PARP13 is enzymatically inactive, it contains four RNA-binding CCCH zinc finger domains and binds to AGO2 in an RNA-dependent manner, suggesting that it either binds to RNA that is attached to AGO2 or that RNA binding to AGO2 results in a conformational change that mediates PARP13 binding. PARP13 is a target for PAR modification and therefore could also target AGO2 for modification by recruiting other PARPs 17 .
The role of AGO2 in cancer progression is complex. Profiling of AGO family members in human colon cancer tissue identified overexpression of AGO2 in cancerous tissue compared with adjacent non-cancerous tissue 83 , and AGO2 was similarly found to be upregulated in human hepatocellular carcinoma, promoting tumour growth and metastasis 84 . By contrast, other reports show that AGO2 overexpression inhibits tumorigenesis by silencing genes that are required for proliferation 85, 86 and that AGO2 expression is downregulated in melanoma 87 and lung adenocarcinoma 86 . Thus, the role of AGO2 and other AGO proteins in tumorigenesis might depend on tumour specificity, the tumour microenvironment and the genetic alterations of the cancers in question. Because of the complex role of AGO2 in cancer, further investigation will be required to determine whether inhibition of AGO2 ADP-ribosylation will have therapeutic benefits. Perhaps one of the most straightforward benefits of modulating miRNA activity via PARP inhibition might be an increase in the effectiveness of siRNA or miRNA therapies, because PAR modification of AGO2 inhibits its miRNA-mediated silencing activity.
Signal transduction. PARP10, a MARgenerating PARP
3 with RNA-and ubiquitinbinding domains, has functions in multiple signalling pathways. It was initially identified 
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Stress granule assembly, which involves PARP5A, PARP12, PARP13, PARP14 and PARP15 as a MYC-interacting protein that inhibits the transformation of rat embryo fibroblasts by MYC and HRAS, but its effect was independent of its ADP-ribosylase activity 88 . This was the first indication of a potential tumour-suppressive role for PARP10 because MYC -a transcription factor that regulates many cellular processes, including cell proliferation -is frequently deregulated in cancer cells and is associated with tumour progression 89 . PARP10 was also recently shown to regulate NF-κB signalling in a manner that is dependent on both PARP10 interacting with polyubiquitin chains on proteins that regulate NF-κB activity and its ADP-ribosylase activity. Exogenous PARP10 expression in both HeLa and U2OS cells resulted in the inhibition of downstream NF-κB target gene expression in response to interleukin-1β (IL-1β) and tumour necrosis factor (TNF) by altering the polyubiquitylation state of several NF-κB signalling intermediates and preventing the translocation of the NF-κB transcription factor subunit p65 (also known as RELA) to the nucleus 57 . Additionally, PARP10 overexpression in HeLa cells inhibited cell proliferation through the induction of apoptosis 90, 91 , although the contribution of altered NF-κB and/or MYC signalling to apoptosis induction was not investigated. PARP10 function in the regulation of NF-κB signalling is physiologically relevant, as short hairpin RNA (shRNA)-mediated and siRNA-mediated knockdown of endogenous PARP10 increased the expression of NF-κB targets in HeLa and U2OS cell lines 57 . PARP10 is enriched in cytoplasmic polyubiquitin-containing foci that can interact with autophagosomes marked by p62 (also known as SQSTM1), which is a ubiquitinbinding autophagy adaptor protein 92 .
Although the role of PARP10 in autophagy has not been investigated, this association is particularly interesting because autophagy is activated in cancer cells and might represent another mechanism to cope with cellular stress [93] [94] [95] . Inhibition of autophagy can sensitize cancer cells to chemotherapy 96 or inhibit tumour growth 97 . The autophagy pathway exerts cytoprotective effects on cancer cells by inhibiting apoptosis and necrosis in response to metabolic stress 98, 99 . As NF-κB signalling can regulate autophagy, PARP10 might represent an important link between these two pathways 100 . Further study of the function of PARP10 in NF-κB signalling will be important to understand its role in normal physiology and disease, and to determine if it does indeed have a function in autophagy regulation.
PARP14 is a MAR-generating PARP that contains three macro domains (TABLE 1) . PARP14 regulates IL-4 signalling by functioning as a transcriptional co-activator of the transcription factor signal transducer and activator of transcription 6 (STAT6) in a mechanism that is dependent on its catalytic activity 59, 101 . B cell proliferation and survival is compromised in splenocytes from Parp14 . PARP14 has also recently been implicated in mediating JNK pro-survival signalling in multiple myeloma cells and is highly expressed in these cells compared with (part b) . Therefore, PARPs function in the activation of DNA damage repair pathways, stress granule assembly, the heat shock response and the ER unfolded protein response (UPR) pathway. Many of these physiological and stress response pathways are misregulated in cancer, raising the possibility that inhibition of these PARP-mediated functions could have therapeutic benefits. PAR, poly(ADP-ribose); RISC, RNA-induced silencing complex.
normal plasma cells 58 . Therefore, PARP14 is a new candidate for therapeutic intervention in haematological malignancies owing to its functions in B cell development (TABLE 1) .
Cell migration. PARP9 and PARP14 are members of the macro PARP subfamilythey contain two and three macro domains, respectively. The macro domains of PARP9 can bind to both free MAR and free PAR, whereas PARP14 macro domains specifically bind to MAR-modified proteins 21, 27 . Both PARP9 and PARP14 are involved in the regulation of cell migration 52, 60 , which is a highly complex process requiring the coordinated activity of multiple proteins that is necessary for the development of metastases 104, 105 . The discovery of regulatory functions for PARP9 and PARP14 in cell migration suggests that they could be important targets for cancer therapy.
PARP9 was originally identified as BAL1 because it is expressed at higher levels in high-risk diffuse large B cell lymphomas compared with low-risk tumours 60 . PARP9 overexpression promotes the migration of B cell lymphoma cells, which suggests that it has a function in the regulation of cell motility 60 . Consistent with this observation, PARP9 knockdown results in defects in the actin cytoskeleton 52 . Although PARP9 is constitutively expressed in cells, its expression can be induced by interferon-γ (IFNγ) 106 , an immunostimulatory cytokine that has been previously implicated in the activation of B cell motility 107, 108 . IFNγ has tumour-suppressive effects by increasing tumour immunogenicity and is clinically used as a cancer treatment; however, many studies also report pro-tumorigenic effects of treatment with IFNγ 109 . This contradiction seems to be a consequence of dosage. Treatment of a low-grade bladder cancer cell line with high concentrations of IFNγ had anti-proliferative effects, whereas low doses of IFNγ resulted in resistance to TNF-mediated cytotoxicity and were associated with an increase in cell migration 110 . Additionally, mammary adenocarcinoma cells expressing low levels of IFNγ were more metastatic than those expressing high levels when evaluated by tail vein injection into BALB/c mice 111 . Furthermore, low surface expression of IFNγR2 (a component of the IFNγ receptor) on T cells results in a proliferative effect on treatment with IFNγ that switches to an apoptotic effect if the levels of IFNγR2 are increased through exogenous expression 112 . One possible model that integrates these disparate findings is that low amounts of IFNγ induce PARP9 expression, which results in upregulation of cell motility and metastasis, whereas higher levels overcome the effects of PARP9 expression and result in anti-proliferative and pro-apoptotic effects. Therefore, the expression levels of PARP9 and other IFNγ-dependent genes should be evaluated following low or high doses of IFNγ treatment.
PARP9 is catalytically inactive based on automodification activity 3, 113 , and how PARP9 functions in cell migration is unknown. It will be important to determine whether binding to MAR or PAR regulates the function of PARP9. If PARP9 is a contributing factor to the pro-metastatic effects of IFNγ treatment, the inhibition of PARP9 function in conjunction with IFNγ could potentially overcome the tumorigenic effects of low levels of IFNγ.
PARP14 associates with focal adhesions, as identified both by biochemical purification of focal adhesion complexes from human foreskin fibroblast cells 114 and by co-immunostaining with focal adhesion proteins in HeLa cells 52 . PARP14 knockdown results in defects in cell migration in adherent cells such that they are unable to effectively retract protrusions and have increased adhesiveness to a fibronectin substrate 52 . These findings indicate that PARP14 regulates focal adhesion turnover 52 . Although metastasis requires the loss of cell-cell contacts, metastatic cells are able to bind to extracellular matrix components that are not bound by cells in primary tumours 115 . Fibronectin and integrin interactions have long been implicated in the promotion of tumour cell invasion and metastasis 116 . Further mechanistic investigation of the function of PARP14 in focal adhesion regulation will be important to determine whether PARP14 is a useful target for the inhibition of metastasis.
Concluding remarks
Recent analysis examining the binding of 185 known PARP inhibitors to bacterially expressed catalytic domains of 14 of the 17 human PARPs showed that almost none of the inhibitors bind to MAR-generating PARPs, and the handful that bind do so with low affinity 6 . These results suggest that selective inhibition of MAR-generating PARPs is possible, and they provide an explanation as to why MAR-dependent phenotypes do not occur on treatment with current inhibitors of PARP1, PARP2, PARP5A and PARP5B.
Within the past several years, data have emerged that identify important cellular functions for MAR-generating PARPs. Many of these functions are disease-relevant and could be attractive targets for the therapeutic inhibition of cancer. Much remains unanswered regarding the mechanism of MAR function, the potential functional interactions between MAR and PAR and the potential regulatory interactions between PARPs. Identifying PARP-specific activating signals and targets, and determining the manner in which protein function is altered upon modification will be important steps for our understanding of MAR. This information will also allow us to better evaluate the therapeutic relevance of MAR inhibition for the treatment of cancer.
Within the past several years, data have emerged that identify important cellular functions for MAR-generating PARPs. Many of these functions are diseaserelevant and could be attractive targets for the therapeutic inhibition of cancer.
